213 related articles for article (PubMed ID: 21422803)
21. BAY 43-9006 inhibition of oncogenic RET mutants.
Carlomagno F; Anaganti S; Guida T; Salvatore G; Troncone G; Wilhelm SM; Santoro M
J Natl Cancer Inst; 2006 Mar; 98(5):326-34. PubMed ID: 16507829
[TBL] [Abstract][Full Text] [Related]
22. Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.
Caenepeel S; Renshaw-Gegg L; Baher A; Bush TL; Baron W; Juan T; Manoukian R; Tasker AS; Polverino A; Hughes PE
J Exp Clin Cancer Res; 2010 Jul; 29(1):96. PubMed ID: 20633291
[TBL] [Abstract][Full Text] [Related]
23. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.
Strock CJ; Park JI; Rosen M; Dionne C; Ruggeri B; Jones-Bolin S; Denmeade SR; Ball DW; Nelkin BD
Cancer Res; 2003 Sep; 63(17):5559-63. PubMed ID: 14500395
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib and thyroid cancer.
Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
[TBL] [Abstract][Full Text] [Related]
25. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.
Vitagliano D; De Falco V; Tamburrino A; Coluzzi S; Troncone G; Chiappetta G; Ciardiello F; Tortora G; Fagin JA; Ryan AJ; Carlomagno F; Santoro M
Endocr Relat Cancer; 2011 Feb; 18(1):1-11. PubMed ID: 20943719
[TBL] [Abstract][Full Text] [Related]
26. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
Wang D; Tang F; Wang S; Jiang Z; Zhang L
Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
[TBL] [Abstract][Full Text] [Related]
27. T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T.
Erickson TA; Shih YP; Fass J; Jang M; Tran E
Thyroid; 2022 Jul; 32(7):789-798. PubMed ID: 35587601
[No Abstract] [Full Text] [Related]
28. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.
Jin N; Jiang T; Rosen DM; Nelkin BD; Ball DW
Clin Cancer Res; 2011 Oct; 17(20):6482-9. PubMed ID: 21831957
[TBL] [Abstract][Full Text] [Related]
29. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
[No Abstract] [Full Text] [Related]
30. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.
Akeno-Stuart N; Croyle M; Knauf JA; Malaguarnera R; Vitagliano D; Santoro M; Stephan C; Grosios K; Wartmann M; Cozens R; Caravatti G; Fabbro D; Lane HA; Fagin JA
Cancer Res; 2007 Jul; 67(14):6956-64. PubMed ID: 17638907
[TBL] [Abstract][Full Text] [Related]
31. Motesanib diphosphate in progressive differentiated thyroid cancer.
Sherman SI; Wirth LJ; Droz JP; Hofmann M; Bastholt L; Martins RG; Licitra L; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Schlumberger MJ;
N Engl J Med; 2008 Jul; 359(1):31-42. PubMed ID: 18596272
[TBL] [Abstract][Full Text] [Related]
32. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer.
Bass MB; Sherman SI; Schlumberger MJ; Davis MT; Kivman L; Khoo HM; Notari KH; Peach M; Hei YJ; Patterson SD
J Clin Endocrinol Metab; 2010 Nov; 95(11):5018-27. PubMed ID: 20739388
[TBL] [Abstract][Full Text] [Related]
33. Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells.
Nicolini V; Cassinelli G; Cuccuru G; Bongarzone I; Petrangolini G; Tortoreto M; Mondellini P; Casalini P; Favini E; Zaffaroni N; Zunino F; Lanzi C
Biochem Pharmacol; 2011 Oct; 82(7):778-88. PubMed ID: 21741956
[TBL] [Abstract][Full Text] [Related]
34. Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation.
Giardino E; Catalano R; Barbieri AM; Treppiedi D; Mangili F; Spada A; Arosio M; Mantovani G; Peverelli E
Mol Cell Endocrinol; 2019 Sep; 495():110519. PubMed ID: 31352037
[TBL] [Abstract][Full Text] [Related]
35. Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.
Gorla L; Mondellini P; Cuccuru G; Miccichè F; Cassinelli G; Cremona M; Pierotti MA; Lanzi C; Bongarzone I
Mol Carcinog; 2009 Mar; 48(3):220-231. PubMed ID: 18756447
[TBL] [Abstract][Full Text] [Related]
36. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
[TBL] [Abstract][Full Text] [Related]
37. Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.
Lopergolo A; Nicolini V; Favini E; Dal Bo L; Tortoreto M; Cominetti D; Folini M; Perego P; Castiglioni V; Scanziani E; Borrello MG; Zaffaroni N; Cassinelli G; Lanzi C
J Clin Endocrinol Metab; 2014 Feb; 99(2):498-509. PubMed ID: 24276455
[TBL] [Abstract][Full Text] [Related]
38. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Kurzrock R; Atkins J; Wheler J; Fu S; Naing A; Busaidy N; Hong D; Sherman S
Ann Oncol; 2013 Sep; 24(9):2256-61. PubMed ID: 23676418
[TBL] [Abstract][Full Text] [Related]
39. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model.
Drosten M; Stiewe T; Pützer BM
Hum Gene Ther; 2003 Jul; 14(10):971-82. PubMed ID: 12869215
[TBL] [Abstract][Full Text] [Related]
40. Targeting RET for thyroid cancer therapy.
Lanzi C; Cassinelli G; Nicolini V; Zunino F
Biochem Pharmacol; 2009 Feb; 77(3):297-309. PubMed ID: 19028457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]